Post-chemotherapeutic CEA and CA19-9 are prognostic factors in patients with colorectal liver metastases treated with hepatic resection after oxaliplatin-based chemotherapy

Anticancer Research

Volumn 35, Issue 4, 2015, Pages 2359-2368

  Sakamoto, Yasuo ^a,b   Miyamoto, Yuji ^a   Beppu, Toru ^a,b   Nitta, Hidetoshi ^a   Imai, Katsunori ^a   Hayashi, Hiromitsu ^a   Baba, Yoshifumi ^a   Yoshida, Naoya ^a   Chikamoto, Akira ^a   Baba, Hideo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Chemotherapy; Colorectal cancer; Colorectal liver metastasis; Hepatectomy

Indexed keywords

BEVACIZUMAB; CA 19-9 ANTIGEN; CAPECITABINE PLUS OXALIPLATIN; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PLATINUM COMPLEX;

ABDOMINAL ABSCESS; ADULT; AGED; ARTICLE; BILE LEAKAGE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LIVER RESECTION; LUNG EMBOLISM; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PLEURA EFFUSION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; SURGICAL INFECTION; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VOLUME; VIRUS ONCOGENE; WILD TYPE; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; BLOOD; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; LIVER NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; SECONDARY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; PROGNOSIS;

EID: 84928395777     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Adam R, Aloia T, Levi F, Wicherts DA, de Haas RJ, Paule B, Bralet MP, Bouchahda M, Machover D, Ducreux M, Castagne V, Azoulay D, and Castaing D: Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 25: 4593-4602, 2007.
2. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghemard O, Levi F, and Bismuth H: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240: 644-657; discussion 657-648, 2004.
3. Beppu T, Hayashi N, Masuda T, Komori H, Horino K, Hayashi H, Okabe H, Baba Y, Kinoshita K, Akira C, Watanebe M, Takamori H, and Baba H: FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases. Anticancer Res 30: 1015-1020, 2010.
4. Beppu T, Miyamoto Y, Sakamoto Y, Imai K, Nitta H, Hayashi H, Chikamoto A, Watanabe M, Ishiko T, and Baba H: Chemo - therapy and targeted therapy for patients with initially unresectable colorectal liver metastases, focusing on conversion hepatectomy and long-term survival. Ann Surg Oncol 21 Suppl 3: S405-413, 2014.
5. Beppu T, Sakamoto Y, Hasegawa K, Honda G, Tanaka K, Kotera Y, Nitta H, Yoshidome H, Hatano E, Ueno M, Takamura H, Baba H, Kosuge T, Kokudo N, Takahashi K, Endo I, Wakabayashi G, Miyazaki M, Uemoto S, Ohta T, Kikuchi K, Yamaue H, Yamamoto M, and Takada T: A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 19: 72-84, 2012.
6. Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D, Majno P, and Engerran L: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224: 509-520; discussion 520-502, 1996.
7. Bogaerts J, Ford R, Sargent D, Schwartz LH, Rubinstein L, Lacombe D, Eisenhauer E, Verweij J, Therasse P, and Party RW: Individual patient data analysis to assess modifications to the RECIST criteria. European journal of cancer 45: 248-260, 2009.
8. Fong Y, Fortner J, Sun RL, Brennan MF, and Blumgart LH: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230 : 309-318; discussion 318-321, 1999.
9. Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, Colvin EK, Nagrial A, Chin VT, Chantrill LA, Samra JS, Gill AJ, Kench JG, Merrett ND, Das A, Musgrove EA, Sutherland RL, and Biankin AV: The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol 23: 1713-1722, 2012.
10. Inoue Y, Hayashi M, Komeda K, Masubuchi S, Yamamoto M, Yamana H, Kayano H, Shimizu T, Asakuma M, Hirokawa F, Miyamoto Y, Takeshita A, Shibayama Y, and Uchiyama K: Resection margin with anatomic or nonanatomic hepatectomy for liver metastasis from colorectal cancer. J Gastrointest Surg 16: 1171-1180, 2012.
11. Ishiguro S: [Pathological diagnosis of colorectal cancer according to Japanese classification of colorectal carcinoma]. Nihon rinsho Japanese journal of clinical medicine 69 Suppl 3: 325-329, 2011.
12. Ishizuka D, Shirai Y, Sakai Y, and Hatakeyama K: Colorectal carcinoma liver metastases: clinical significance of preoperative measurement of serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels. Int J Colorectal Dis 16: 32-37, 2001.
13. Kanemitsu Y, Kato T, Shimizu Y, Inaba Y, Shimada Y, Nakamura K, Sato A, and Moriya Y: A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer: Japan Clinical Oncology Group Study JCOG0603. Jpn J Clin Oncol 39: 406-409, 2009.
14. Katoh H, Yamashita K, Kokuba Y, Satoh T, Ozawa H, Hatate K, Ihara A, Nakamura T, Onosato W, and Watanabe M: Surgical resection of stage IV colorectal cancer and prognosis. World J Surg 32 : 1130-1137, 2008.
15. Mima K, Beppu T, Chikamoto A, Miyamoto Y, Nakagawa S, Kuroki H, Okabe H, Hayashi H, Sakamoto Y, Watanabe M, Kikuchi K, and Baba H: Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver meta stases after effective chemotherapy is a safe procedure with a low incidence of local recurrence. Int J Clin Oncol 18: 847-855, 2013.
16. Minagawa M, Yamamoto J, Kosuge T, Matsuyama Y, Miyagawa S, and Makuuchi M: Simplified staging system for predicting the prognosis of patients with resectable liver metastasis: development and validation. Arch Surg 142: 269-276; discussion 277, 2007.
17. Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, Nitti D, Torri V, Elias D, O'Callaghan C, Langer B, Martignoni G, Bouche O, Lazorthes F, Van Cutsem E, Bedenne L, Moore MJ, and Rougier P: Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 26: 4906-4911, 2008.
18. Mitsuyama Y, Shiba H, Haruki K, Fujiwara Y, Furukawa K, Iida T, Hayashi T, Ogawa M, Ishida Y, Misawa T, Kashiwagi H, and Yanaga K: Carcinoembryonic antigen and carbohydrate antigen 19-9 are prognostic predictors of colorectal cancer with unresectable liver metastasis. Oncol Lett 3: 767-771, 2012.
19. Nakagoe T, Sawai T, Tsuji T, Jibiki MA, Nanashima A, Yamaguchi H, Yasutake T, Ayabe H, Arisawa K, and Ishikawa H: Difference in prognostic value between sialyl Lewis(a) and sialyl Lewis(x) antigen levels in the preoperative serum of gastric cancer patients. J Clin Gastroenterol 34 : 408-415, 2002.
20. Nakayama T, Watanabe M, Teramoto T, and Kitajima M: CA19-9 as a predictor of recurrence in patients with colorectal cancer. J Surg Oncol 66 : 238-243, 1997.
21. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, and Jaeck D: Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 77: 1254-1262, 1996.
22. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem E, Scheithauer W, and Gruenberger T: Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14: 1208-1215, 2013.
23. Ohtsuka M, Ito H, Kimura F, Shimizu H, Togawa A, Yoshidome H, and Miyazaki M: Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg 89: 1525-1531, 2002.
24. Park IJ, Choi GS, and Jun SH: Prognostic value of serum tumor antigen CA19-9 after curative resection of colorectal cancer. Anticancer Res 29 : 4303-4308, 2009.
25. Sakamoto Y, Beppu T, Miyamoto Y, Okabe H, Ida S, Imai K, Chikamoto A, Watanabe M, Takamori H, and Baba H: Feasibility and short-term outcome of adjuvant FOLFOX after resection of colorectal liver metastases. J Hepatobiliary Pancreat Sci 20 : 307-312, 2013.
26. Schindl M, Wigmore SJ, Currie EJ, Laengle F, and Garden OJ: Prognostic scoring in colorectal cancer liver metastases: development and validation. Arch Surg 140 : 183-189, 2005.
27. Sorbye H, Mauer M, Gruenberger T, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Van Cutsem E, Scheithauer W, Lutz MP, and Nordlinger B: Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg 255: 534-539, 2012.
28. Stangl R, Altendorf-Hofmann A, Charnley RM, and Scheele J: Factors influencing the natural history of colorectal liver metastases. Lancet 343 : 1405-1410, 1994.
29. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 92 : 205-216, 2000.
30. Zhang S, Gao F, Luo J, and Yang J: Prognostic factors in survival of colorectal cancer patients with synchronous liver metastasis. Colorectal Dis 12: 754-761, 2010.